Connect with us

Hi, what are you looking for?


Looking beyond tobacco, BAT tries Canadian pot luck

Stock Markets50 minutes ago (Mar 11, 2021 08:30AM ET)


(C) Reuters. FILE PHOTO: Signage is seen at the London offices of British American Tobacco, in London, Britain


(Reuters) – British American Tobacco (NYSE:BTI) said on Thursday it will buy a nearly 20% stake in Canada-based cannabis producer Organigram for about 126 million pounds ($175.81 million) as it diversifies beyond its main tobacco business.

Organigram grows cannabis and makes cannabis-derived products in Canada where marijuana was legalised in 2018.

Big tobacco and liquor companies in North America have already made large investments in the nascent industry, with cannabis seen as a less-harmful alternative to cigarettes.

And with top Democratic lawmakers in the United States also promising to decriminalise marijuana use, analysts and experts predict record investment in the industry this year.

The deal with Organigram will give BAT (LON:BATS) access to R&D technologies, product innovation and cannabis expertise, it said in a statement.

A ‘Centre of Excellence’ will be established at Organigram’s facility in New Brunswick (NYSE:BC), Canada, to focus on developing next-generation cannabis products with an initial focus on natural remedy cannabidiol.

Both BAT and Organigram will contribute scientists, researchers, and product developers to the centre, BAT said, while the unit which acquires the stake in Organigram will become its largest shareholder and can appoint two directors to the Canadian company’s board.

Organigram’s U.S.-listed shares surged around 50% to $4.32 in premarket trading on the Nasdaq. BAT’s London-listed shares were flat.

“Organigram has a proven track record of consumer-led innovation and developing high quality adult-use recreational and medical cannabis products, which are legally available in Canada,” BAT said.

Both parties will able to commercialise under their own brands any products developed from the collaboration.

“As global cannabis deregulation gains pace, led by the US, we have been approached by an increasing number of Big Tobacco, Big Pharma and leading FMCG companies, looking to invest in the Cannabis sector,” said Tristan Gervais, Chrystal Capital’s Head of Cannabis advisory at Europe’s Cannabis Merchant Bank.

Marlboro maker Altria (NYSE:MO) has invested in pot producer Cronos Group (NASDAQ:CRON) Inc, while Corona beer-maker Constellation Brands Inc (NYSE:STZ) has a stake in Canopy Growth (NASDAQ:CGC), the largest cannabis company globally by market value.

Looking beyond tobacco, BAT tries Canadian pot luck

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.


Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione.


Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum.


Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora.

Disclaimer: it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial or health advice. Copyright © 2021 Buzz Clever. All Rights Reserved